Citigroup Maintains Buy on Rigel Pharmaceuticals, Lowers Price Target to $69

Benzinga Newsdesk www.benzinga.com Negative 52.0%

Neg 52% Neu 0% Pos 0%

Citigroup analyst Yigal Nochomovitz maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and lowers the price target from $71 to $69.